Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rember dose-ranging study in Alzheimer's disease
NCT00515333Phase 2Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Aug 2004
- Primary completion
- Dec 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of methylene blue in Alzheimer's disease (AD), sponsored by TauRx Therapeutics Ltd. Started Aug 2004; status: completed.
02
Drugs
methylene blue
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00515333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515333.